BIO's Testimony to the House Appropriations, Labor HHS Subcommittee on the President's FY 2013 Budget Request for the National Institutes of Health (NIH)
Good morning Chairman Rehberg, Ranking Member DeLauro, Members of the Committee, ladies, and gentlemen. I am Scott Koenig, President and Chief Executive Officer of MacroGenics, Inc. and Chairman of the Board of Applied Genetic Technologies Corp (AGTC). I am appearing before this Committee on behalf of the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 companies, academic institutions, state biotechnology centers, and related organizations in all 50 states.
I am a scientist, physician, and entrepreneur and have worked both at the National Institutes of Health (NIH) and in the biotechnology industry for the past twenty-eight years. During my career I have held positions including Senior Vice President of Research at MedImmune, Inc., co-founder and CEO of MacroGenics, Inc., and Board member of AGTC. During this time I have been involved in the development of multiple biological products, such as a therapy to prevent a fatal respiratory viral illness in premature infants, a vaccine to prevent cervical cancer, and a number of other promising biological therapeutics still in development such as treatments for juvenile diabetes and many types of cancer.
It is my privilege to testify before the Subcommittee today to discuss the importance of funding NIH and specifically to talk about the newly-formed National Center for Advancing Translational Science (NCATS). I will discuss the opportunities and potential benefits of NCATS working with the scientific community to find 2
solutions to critical scientific barriers and developing novel scientific approaches, methodologies, and tools to improve efficiencies in how we, as an industry, research and develop breakthrough treatments and therapies.